Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >
Impact of incretin-related agents on endothelial cell function
This item is licensed under:Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported
Title: | Impact of incretin-related agents on endothelial cell function |
Authors: | Nomoto, Hiroshi Browse this author | Miyoshi, Hideaki Browse this author →KAKEN DB | Nakamura, Akinobu Browse this author →KAKEN DB | Atsumi, Tatsuya Browse this author →KAKEN DB | Manda, Naoki Browse this author | Kurihara, Yoshio Browse this author | Aoki, Shin Browse this author | on behalf of SAIS Study Group Browse this author |
Keywords: | GLP-1 analogue | DPP-4 inhibitor | endothelial cell function |
Issue Date: | Jan-2017 |
Publisher: | Wolters Kluwer |
Journal Title: | Clinical Trials in Degenerative Diseases |
Volume: | 2 |
Issue: | 1 |
Start Page: | 7 |
End Page: | 11 |
Publisher DOI: | 10.4103/2542-3975.202726 |
Abstract: | Incretin-related drugs, such as dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) analogues, have been clinically available and widely used to treat patients with type 2 diabetes mellitus. Accumulating evidence indicates that these agents exert glycemic control and have various other favorable effects, including prevention of atherosclerosis. It is important to assess and manage early-phase atherosclerosis, but whether diabetic therapeutics including incretin-related drugs improve or maintain vascular endothelial cell function has not been fully determined. We previously published prospective clinical trials focused on flow-mediated dilation in patients with type 2 diabetes, who did not have severe atherosclerosis, using two different incretin-related drugs: a DPP-4 inhibitor and a GLP-1 analogue. These trials showed that these therapeutic agents did not improve endothelial cell function. In this article, we discuss how incretin-related drugs contribute, if at all, to vascular endothelial cell function, atherosclerosis, and beta-cell function, based on our clinical trials and previous evidence. |
Rights: | http://creativecommons.org/licenses/by-nc-sa/3.0/ |
Type: | article |
URI: | http://hdl.handle.net/2115/67909 |
Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 三好 秀明
|